Impella
Impella 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Coronary Artery Disease、High Risk Percutaneous Coronary Intervention、Interventional Cardiology、Mechanical Circulatory Support。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
0 项
已进入 III/IV 期
10 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Supira Medical
- University Hospital, Geneva
- Insel Gruppe AG, University Hospital Bern
- Assistance Publique - Hôpitaux de Paris
- Assistance Publique Hopitaux De Marseille
- Columbia University
- Medical University of Vienna
- Amsterdam UMC, location VUmc
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
瑞士、法国、美国、奥地利、荷兰、德国、意大利、Hungary、Poland、英国
正在招募患者的 Impella 研究
The ECMOCYP (cytochromes P450 Activity) Study
不适用招募中瑞士NCT06662084CARDSUP - SWISS Circulatory Support Registry
不适用招募中瑞士NCT04117230Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock
不适用招募中法国NCT04184635Evaluation of the Efficacy of Early Implantation of a Percutaneous Left Ventricular Assist Devices in Acute Coronary Syndrome Complicated by Cardiogenic Shock Compared to Conventional Therapy: a Prospective, Multicenter, Randomized, Controlled and Open-label Clinical Trial
不适用招募中法国NCT05366452Impella Reverse Remodeling in End-Stage Heart Failure
不适用招募中美国NCT06800716OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science
不适用招募中奥地利NCT07619144Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures
不适用招募中荷兰NCT07380217Abiomed Impella RT-DAQ - Observational Study
不适用招募中德国意大利瑞士NCT06308055Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
不适用招募中德国NCT06765226Factors Influencing Outcomes in ECMO and Impella Patients: Metabolic and Thyroid Hormone Dynamics
不适用招募中HungaryNCT07885618INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
不适用招募中美国NCT06965504Echocardiographic Assessment of the Effect of Impella on Biventricular Function
不适用招募中美国NCT07534462Lower Silesia Cardiogenic Shock Initiative
不适用招募中PolandNCT05465200Early Left Ventricular unLoading by Impella vs Intra-aortic Balloon Pump
不适用招募中法国NCT06645990Resuscitative TEE Collaborative Registry
不适用招募中美国NCT04972526ELEVATE High-Risk PCI Pivotal Study
不适用招募中美国NCT07001332Genomic Determinants of Outcome in Cardiogenic Shock
不适用招募中英国NCT05728359Cardiogenic Shock Working Group Registry
不适用招募中美国NCT04682483IMPELLA, Complications and Tolerance
不适用招募中法国NCT06644963Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
不适用招募中德国NCT07655479Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
不适用招募中美国NCT07296744Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
不适用招募中美国NCT06964685
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。